Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ironwood Phase III Data Emphasizes Likely Linzess Label Expansion

Executive Summary

Ironwood presented Phase III data on Linzess (linaclotide) at Digestive Disease Week for the treatment of 6-17 year-olds with functional constipation; US FDA approval is expected in a month.

You may also be interested in...



Ironwood Gears Up To Compete In Competitive Gastrointestinal Markets

With the acquisition of Swiss biotech firm VectivBio in late June, Ironwood Pharmaceuticals has firmly positioned itself as a gastrointestinal-focused company.

Ironwood Paying $1bn For VectivBio To Extend Its GI Franchise Beyond Linzess

Ironwood said it believes VectivBio’s once-weekly GLP-2 analog apraglutide is differentiated from Takeda’s once-daily Gattex in short bowel syndrome and could generate $1bn in peak sales.

Ironwood’s Phase III Data Could Expand Linzess Market Share

The company also hopes that positive safety data for pediatric patients could help with discussions with the FDA to make an OTC version of the drug.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC148338

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel